{"hands_on_practices": [{"introduction": "A cornerstone of managing nasal disorders is the ability to objectively quantify airway obstruction. This practice grounds the clinical technique of rhinomanometry in the fundamental principles of fluid dynamics. By deriving the relationship between pressure, flow, and resistance, you will translate the subjective symptom of nasal blockage into a measurable physical parameter, a crucial skill for diagnosing conditions like rhinitis medicamentosa and assessing treatment efficacy [@problem_id:5053086].", "problem": "A patient with chronic non-allergic nasal symptoms consistent with rhinitis medicamentosa, due to prolonged topical vasoconstrictor use, undergoes posterior rhinomanometry (PR) to quantify nasal airway mechanics. In PR, a catheter measures the posterior pressure near the choana in the nasopharynx while a flow sensor at a sealed face mask measures the volumetric airflow. Assume the following fundamental bases: steady incompressible flow through an airway, conservation of mass, Newtonian fluid behavior for air in the physiologic range, and laminar viscous flow in conduits producing a linear relationship between pressure drop and volumetric flow rate. Starting from these bases, derive the general linear relation between pressure drop across a resistive airway segment and volumetric flow rate, and define nasal airway resistance accordingly. State the assumptions required for the derivation and identify the anatomical sites that the pressure measurements represent in posterior rhinomanometry.\n\nFor this patient, the following measurements were obtained at peak steady inspiratory flow during quiet breathing:\n- Baseline (with rebound congestion): transnasal pressure drop $\\Delta P_{\\mathrm{baseline}} = 210 \\ \\mathrm{Pa}$ and volumetric flow $Q_{\\mathrm{baseline}} = 0.35 \\ \\mathrm{L/s}$.\n- After discontinuation of the decongestant with clinical improvement: transnasal pressure drop $\\Delta P_{\\mathrm{post}} = 90 \\ \\mathrm{Pa}$ and volumetric flow $Q_{\\mathrm{post}} = 0.50 \\ \\mathrm{L/s}$.\n\nUsing your derived definition of nasal resistance, express the ratio $R_{\\mathrm{baseline}} / R_{\\mathrm{post}}$ solely in terms of the measured variables and compute its numerical value. Round your final ratio to three significant figures. Express the ratio as a unitless number. All necessary unit conversions should be performed explicitly.", "solution": "The problem statement is evaluated for validity.\n\n### Step 1: Extract Givens\n- **Context**: A patient with rhinitis medicamentosa.\n- **Measurement Technique**: Posterior rhinomanometry (PR).\n- **Fundamental Bases for Derivation**:\n    1. Steady incompressible flow.\n    2. Conservation of mass.\n    3. Newtonian fluid behavior for air.\n    4. Laminar viscous flow in conduits producing a linear relationship between pressure drop and volumetric flow rate.\n- **Task 1**: Derive the general linear relation between pressure drop ($\\Delta P$) and volumetric flow rate ($Q$).\n- **Task 2**: Define nasal airway resistance ($R$).\n- **Task 3**: State the assumptions required.\n- **Task 4**: Identify anatomical sites for pressure measurements in PR.\n- **Baseline Measurements**:\n    - $\\Delta P_{\\mathrm{baseline}} = 210 \\ \\mathrm{Pa}$\n    - $Q_{\\mathrm{baseline}} = 0.35 \\ \\mathrm{L/s}$\n- **Post-Treatment Measurements**:\n    - $\\Delta P_{\\mathrm{post}} = 90 \\ \\mathrm{Pa}$\n    - $Q_{\\mathrm{post}} = 0.50 \\ \\mathrm{L/s}$\n- **Task 5**: Express the ratio $R_{\\mathrm{baseline}} / R_{\\mathrm{post}}$ in terms of measured variables.\n- **Task 6**: Compute the numerical value of the ratio, rounded to three significant figures.\n\n### Step 2: Validate Using Extracted Givens\n1.  **Scientifically Grounded**: The problem is based on the application of fluid dynamics principles to characterize airflow in the human nasal passage, a standard practice in otorhinolaryngology and biomedical engineering. The physical model (approximating nasal airflow as laminar flow in a conduit) and the resulting concept of nasal resistance are well-established. The clinical context (rhinitis medicamentosa) and the measurement values are physiologically realistic. The problem is scientifically sound.\n2.  **Well-Posed**: The problem provides all necessary data and a clear set of tasks. The derivation is guided by the provided \"fundamental bases,\" and the calculation is a direct application of the derived formula using the given data. A unique and meaningful solution exists.\n3.  **Objective**: The language is precise, quantitative, and free of subjective claims.\n4.  **Complete and Consistent**: The problem is self-contained. The provided data are consistent with the clinical scenario: a higher pressure drop is required for a lower flow rate at baseline (high resistance due to congestion), and a lower pressure drop is required for a higher flow rate after treatment (lower resistance due to improvement).\n5.  **Unrealistic or Infeasible**: The assumptions, such as laminar flow, are standard simplifications for this type of analysis. The pressure and flow values are within the physiological range for quiet breathing. The problem is feasible.\n\n### Step 3: Verdict and Action\nThe problem is scientifically and logically valid. A full solution will be provided.\n\n### Derivation, Definitions, and Assumptions\n\nThe problem requires a derivation of the relationship between pressure drop and flow rate, starting from the given fundamental bases. The most crucial basis provided is that of \"laminar viscous flow in conduits producing a linear relationship between pressure drop and volumetric flow rate.\" This statement is a direct assertion of the physical law governing the system.\n\nLet $\\Delta P$ represent the pressure drop across a resistive airway segment, and let $Q$ be the volumetric flow rate of air through that segment. The assertion of a linear relationship means that the pressure drop is directly proportional to the flow rate:\n$$\n\\Delta P \\propto Q\n$$\nTo convert this proportionality into an equation, a constant of proportionality is introduced. This constant is defined as the airway resistance, denoted by $R$. The resulting equation is the general linear relation sought:\n$$\n\\Delta P = R \\cdot Q\n$$\nThis relationship is analogous to Ohm's law in electrical circuits, $V = I R$, where voltage drop ($V$) is analogous to pressure drop ($\\Delta P$), current ($I$) is analogous to flow rate ($Q$), and electrical resistance is analogous to fluidic resistance ($R$).\n\nFrom this equation, nasal airway resistance $R$ is formally defined as the ratio of the transnasal pressure drop to the volumetric flow rate:\n$$\nR = \\frac{\\Delta P}{Q}\n$$\nThe primary assumptions underpinning this model, as stated or implied by the problem, are:\n1.  **Steady Flow**: The flow rate $Q$ and pressure drop $\\Delta P$ are considered constant in time during the measurement. This is approximated by measuring at the point of peak steady inspiratory flow.\n2.  **Incompressible Flow**: The density of air is assumed to be constant as it flows through the nasal passages. This is an excellent approximation for the low Mach numbers associated with human breathing.\n3.  **Newtonian Fluid**: Air is treated as a Newtonian fluid, meaning its viscosity is constant and independent of the shear rate. This is accurate for air under physiological conditions.\n4.  **Laminar Flow**: The flow regime is assumed to be laminar (non-turbulent). This is a simplification, as flow in the nasal cavity can have turbulent components, especially at constrictions or high flow rates. However, it is the basis for the linear pressure-flow relationship described by the Hagen-Poiseuille equation for an idealized tube.\n5.  **Rigid Airway**: The nasal passages are assumed to have rigid walls that do not deform in response to the pressure changes during breathing.\n\nIn posterior rhinomanometry, the transnasal pressure drop ($\\Delta P$) is measured between two specific sites. The posterior pressure is measured by a catheter placed in the **nasopharynx** (the part of the pharynx behind the nose and above the soft palate, at the level of the choanae). The anterior or reference pressure is the ambient atmospheric pressure, measured at the opening of the face mask. Therefore, the measurement represents the pressure drop required to move air from the atmosphere, through the inlet of the nostril (nares), through the entire nasal cavity, and into the nasopharynx.\n\n### Calculation of the Resistance Ratio\n\nThe resistance at baseline, $R_{\\mathrm{baseline}}$, and post-treatment, $R_{\\mathrm{post}}$, can be calculated using the definition of resistance derived above.\n\nBaseline resistance:\n$$\nR_{\\mathrm{baseline}} = \\frac{\\Delta P_{\\mathrm{baseline}}}{Q_{\\mathrm{baseline}}}\n$$\nPost-treatment resistance:\n$$\nR_{\\mathrm{post}} = \\frac{\\Delta P_{\\mathrm{post}}}{Q_{\\mathrm{post}}}\n$$\nThe problem asks for the ratio $R_{\\mathrm{baseline}} / R_{\\mathrm{post}}$. We can express this ratio solely in terms of the measured variables by substituting the expressions for each resistance:\n$$\n\\frac{R_{\\mathrm{baseline}}}{R_{\\mathrm{post}}} = \\frac{\\left( \\frac{\\Delta P_{\\mathrm{baseline}}}{Q_{\\mathrm{baseline}}} \\right)}{\\left( \\frac{\\Delta P_{\\mathrm{post}}}{Q_{\\mathrm{post}}} \\right)}\n$$\nSimplifying this compound fraction gives the expression in terms of the measured variables:\n$$\n\\frac{R_{\\mathrm{baseline}}}{R_{\\mathrm{post}}} = \\frac{\\Delta P_{\\mathrm{baseline}}}{Q_{\\mathrm{baseline}}} \\cdot \\frac{Q_{\\mathrm{post}}}{\\Delta P_{\\mathrm{post}}} = \\left(\\frac{\\Delta P_{\\mathrm{baseline}}}{\\Delta P_{\\mathrm{post}}}\\right) \\left(\\frac{Q_{\\mathrm{post}}}{Q_{\\mathrm{baseline}}}\\right)\n$$\nNow, we substitute the provided numerical values:\n- $\\Delta P_{\\mathrm{baseline}} = 210 \\ \\mathrm{Pa}$\n- $Q_{\\mathrm{baseline}} = 0.35 \\ \\mathrm{L/s}$\n- $\\Delta P_{\\mathrm{post}} = 90 \\ \\mathrm{Pa}$\n- $Q_{\\mathrm{post}} = 0.50 \\ \\mathrm{L/s}$\n\nThe units for pressure ($\\mathrm{Pa}$) and flow rate ($\\mathrm{L/s}$) are consistent between the baseline and post-treatment measurements. Therefore, when the ratio is computed, the units will cancel out, yielding a dimensionless number. No unit conversion is necessary for the calculation of the ratio. For instance, converting flow from $\\mathrm{L/s}$ to $\\mathrm{m^3/s}$ would introduce a factor of $10^{-3}$ in both the numerator and the denominator of the flow ratio, which would cancel.\n\nSubstituting the values into the derived expression for the ratio:\n$$\n\\frac{R_{\\mathrm{baseline}}}{R_{\\mathrm{post}}} = \\left(\\frac{210 \\ \\mathrm{Pa}}{90 \\ \\mathrm{Pa}}\\right) \\left(\\frac{0.50 \\ \\mathrm{L/s}}{0.35 \\ \\mathrm{L/s}}\\right)\n$$\nThe units cancel as expected. We proceed with the numerical calculation:\n$$\n\\frac{R_{\\mathrm{baseline}}}{R_{\\mathrm{post}}} = \\left(\\frac{210}{90}\\right) \\left(\\frac{0.50}{0.35}\\right)\n$$\nSimplify each fraction:\n$$\n\\frac{210}{90} = \\frac{21}{9} = \\frac{7}{3}\n$$\n$$\n\\frac{0.50}{0.35} = \\frac{50}{35} = \\frac{10}{7}\n$$\nNow, multiply the simplified fractions:\n$$\n\\frac{R_{\\mathrm{baseline}}}{R_{\\mathrm{post}}} = \\frac{7}{3} \\cdot \\frac{10}{7} = \\frac{10}{3}\n$$\nThe exact value of the ratio is $10/3$. As a decimal, this is $3.333...$. The problem requires the answer to be rounded to three significant figures.\n$$\n\\frac{R_{\\mathrm{baseline}}}{R_{\\mathrm{post}}} \\approx 3.33\n$$\nThis result indicates that the patient's nasal airway resistance was $3.33$ times higher at baseline (during the phase of rebound congestion) compared to after treatment and recovery.", "answer": "$$\\boxed{3.33}$$", "id": "5053086"}, {"introduction": "Effective management of non-allergic rhinitis hinges on accurate diagnosis of its specific subtypes, such as Nonallergic Rhinitis with Eosinophilia Syndrome (NARES). This exercise will guide you through the statistical evaluation of a diagnostic test using nasal cytology. You will learn to compute a test's intrinsic characteristics—sensitivity and specificity—and then apply Bayes' theorem to determine its predictive value in a real-world clinical setting, highlighting how test performance is critically linked to disease prevalence [@problem_id:5053105].", "problem": "A clinician is evaluating nasal cytology as a diagnostic test for Nonallergic Rhinitis with Eosinophilia Syndrome (NARES) within the non-allergic rhinitis spectrum, which also includes vasomotor rhinitis and rhinitis medicamentosa. The test considers a nasal smear positive if it shows more than $10$ eosinophils per high-power field. In a prospective cohort of $400$ adults with chronic rhinitis referred to an Ear, Nose, and Throat (ENT) clinic, all decongestants were withheld for $48$ hours to minimize acute pharmacologic effects of rhinitis medicamentosa on mucosal cells, and a reference standard based on clinical criteria plus blinded histopathology classified patients as follows:\n- True NARES: $160$ patients, of whom $136$ had positive nasal cytology and $24$ had negative nasal cytology.\n- Non-NARES: $240$ patients, of whom $48$ had positive nasal cytology and $192$ had negative nasal cytology.\n\nStarting from the formal definitions of sensitivity and specificity, compute the sensitivity and specificity of nasal cytology for diagnosing NARES from these data. Then, using Bayes’ theorem as the fundamental base, derive the positive predictive value as a function of disease prevalence $p$ and evaluate it for a primary care setting where the prevalence of NARES among patients presenting with chronic rhinitis is $p=0.30$. Round your final numeric result to four significant figures and express it as a decimal fraction (no percentage sign).", "solution": "The problem provides data from a diagnostic accuracy study and asks for the calculation of sensitivity, specificity, and positive predictive value (PPV). The problem statement is well-posed, scientifically grounded, and contains all necessary information for a unique solution.\n\nFirst, we define the events and population counts based on the provided data.\nLet $D^+$ represent the event that a patient has True NARES (Disease Positive).\nLet $D^-$ represent the event that a patient does not have NARES (Disease Negative).\nLet $T^+$ represent a positive nasal cytology test result.\nLet $T^-$ represent a negative nasal cytology test result.\n\nFrom the problem statement, we are given the following counts:\nThe total number of patients with NARES is $160$.\nThe number of patients with NARES and a positive test (True Positives, $TP$) is $136$.\nThe number of patients with NARES and a negative test (False Negatives, $FN$) is $24$.\nThe total number of patients without NARES is $240$.\nThe number of patients without NARES and a positive test (False Positives, $FP$) is $48$.\nThe number of patients without NARES and a negative test (True Negatives, $TN$) is $192$.\nThe total cohort size is $160 + 240 = 400$. The individual counts are consistent: $136 + 24 = 160$ and $48 + 192 = 240$.\n\nThe problem requires us to first compute the sensitivity and specificity of the nasal cytology test.\n\nSensitivity (Sens) is the probability of a positive test result given that the patient has the disease. It is the proportion of true positives among all diseased individuals.\n$$ \\text{Sensitivity} = P(T^+ | D^+) = \\frac{TP}{TP + FN} $$\nSubstituting the given values:\n$$ \\text{Sensitivity} = \\frac{136}{136 + 24} = \\frac{136}{160} $$\nSimplifying the fraction:\n$$ \\text{Sensitivity} = \\frac{17 \\times 8}{20 \\times 8} = \\frac{17}{20} = 0.85 $$\n\nSpecificity (Spec) is the probability of a negative test result given that the patient does not have the disease. It is the proportion of true negatives among all non-diseased individuals.\n$$ \\text{Specificity} = P(T^- | D^-) = \\frac{TN}{TN + FP} $$\nSubstituting the given values:\n$$ \\text{Specificity} = \\frac{192}{192 + 48} = \\frac{192}{240} $$\nSimplifying the fraction:\n$$ \\text{Specificity} = \\frac{4 \\times 48}{5 \\times 48} = \\frac{4}{5} = 0.80 $$\n\nNext, the problem requires the derivation of the Positive Predictive Value (PPV) as a function of disease prevalence, $p$, using Bayes' theorem, and its evaluation for $p=0.30$.\nThe PPV is the probability that a patient has the disease given that they have a positive test result, i.e., $P(D^+ | T^+)$.\n\nAccording to Bayes' theorem:\n$$ P(D^+ | T^+) = \\frac{P(T^+ | D^+) P(D^+)}{P(T^+)} $$\nThe denominator, $P(T^+)$, is the overall probability of a positive test. It can be expanded using the law of total probability:\n$$ P(T^+) = P(T^+ | D^+) P(D^+) + P(T^+ | D^-) P(D^-) $$\nWe can express the terms in this formula using sensitivity, specificity, and prevalence ($p$):\n- $P(D^+) = p$ (Prevalence of the disease)\n- $P(D^-) = 1 - p$\n- $P(T^+ | D^+) = \\text{Sensitivity}$\n- $P(T^+ | D^-)$ is the probability of a positive test in a non-diseased person. This is equal to $1 - P(T^- | D^-) = 1 - \\text{Specificity}$.\n\nSubstituting these into the expression for $P(T^+)$:\n$$ P(T^+) = (\\text{Sensitivity}) \\cdot p + (1 - \\text{Specificity}) \\cdot (1 - p) $$\nNow, substituting this back into the Bayes' theorem formula for PPV:\n$$ \\text{PPV}(p) = P(D^+ | T^+) = \\frac{(\\text{Sensitivity}) \\cdot p}{(\\text{Sensitivity}) \\cdot p + (1 - \\text{Specificity}) \\cdot (1 - p)} $$\nThis is the derived expression for PPV as a function of prevalence $p$.\n\nFinally, we evaluate this expression for a prevalence of $p = 0.30$, using the calculated values for sensitivity and specificity.\n$$ \\text{Sensitivity} = 0.85 $$\n$$ \\text{Specificity} = 0.80 $$\n$$ p = 0.30 $$\n\n$$ \\text{PPV}(0.30) = \\frac{(0.85) \\cdot (0.30)}{(0.85) \\cdot (0.30) + (1 - 0.80) \\cdot (1 - 0.30)} $$\n$$ \\text{PPV}(0.30) = \\frac{0.255}{0.255 + (0.20) \\cdot (0.70)} $$\n$$ \\text{PPV}(0.30) = \\frac{0.255}{0.255 + 0.140} $$\n$$ \\text{PPV}(0.30) = \\frac{0.255}{0.395} $$\nTo perform the division and round to four significant figures:\n$$ \\frac{0.255}{0.395} \\approx 0.64556962... $$\nRounding to four significant figures gives $0.6456$.\nThis result signifies that for a patient in a primary care setting (where prevalence is $30\\%$) who tests positive with nasal cytology, there is approximately a $64.56\\%$ probability that they truly have NARES.", "answer": "$$\n\\boxed{0.6456}\n$$", "id": "5053105"}, {"introduction": "Treating rhinitis medicamentosa presents a significant clinical challenge, centered on weaning patients off topical decongestants without causing severe rebound congestion. This advanced practice utilizes pharmacokinetic/pharmacodynamic (PK/PD) modeling to simulate and compare different weaning protocols. By constructing a mathematical model that captures both drug effect and receptor desensitization, you will gain a deeper, quantitative understanding of the dynamics of withdrawal and the rationale behind therapeutic strategies [@problem_id:5053084].", "problem": "A patient with rhinitis medicamentosa secondary to prolonged overuse of a topical nasal alpha-adrenergic agonist is transitioned off therapy. Model the pharmacokinetic/pharmacodynamic (PK/PD) consequences on nasal congestion using a linear, one-compartment effect model for drug effect and a first-order receptor desensitization model. Let the instantaneous drug effect be $D(t)$ and the receptor-driven desensitization (which increases congestion) be $R(t)$. Assume the following foundational, well-tested dynamics:\n\n- The drug effect compartment follows $ \\frac{dD}{dt} = -k_{d} D + u(t) $, where $k_{d} = \\ln(2)/t_{1/2,d}$ and $t_{1/2,d}$ is the effect-compartment half-life.\n- The receptor desensitization follows $ \\frac{dR}{dt} = -k_{r} R + g D $, where $k_{r} = \\ln(2)/t_{1/2,r}$ and $t_{1/2,r}$ is the desensitization recovery half-life. Choose $g$ so that in steady state with constant input the system satisfies $R_{\\mathrm{ss}} = D_{\\mathrm{ss}}$.\n\nThe patient has been on chronic overuse before $t=0$ at a constant average input $u_{\\mathrm{ss}}$ that maintained a steady state $D_{\\mathrm{ss}} = 1$ and $R_{\\mathrm{ss}} = 1$. At $t=0$, two weaning strategies are compared over the horizon $t \\in [0, T]$ with $T = 72$:\n\n1. Abrupt cessation: $u(t) = 0$ for $t \\in [0, T]$.\n2. Gradual dose spacing: approximate the reduction in dosing frequency (from every $8$ hours to every $24$ hours) by a reduction in average input to $u(t) = u_{\\mathrm{ss}}/3$ for $t \\in [0, T]$.\n\nAssume $t_{1/2,d} = 6$ hours and $t_{1/2,r} = 24$ hours. Define the congestion severity relative to baseline as $C(t) = a R(t) - b D(t)$ with $a = 1$ and $b = 1$. Let the area under the effect curve (AUEC) for congestion be $Q = \\int_{0}^{T} C(t)\\, dt$. Using the stated dynamics and initial conditions $D(0^{-}) = 1$, $R(0^{-}) = 1$, compute the ratio $Q_{\\mathrm{abrupt}}/Q_{\\mathrm{gradual}}$. Express the final ratio as a pure number with no units. No rounding is required.", "solution": "We start from the stated linear differential equations. The drug effect compartment follows $ \\frac{dD}{dt} = -k_{d} D + u(t) $ and the receptor desensitization follows $ \\frac{dR}{dt} = -k_{r} R + g D $. To enforce $R_{\\mathrm{ss}} = D_{\\mathrm{ss}}$ under a constant input $u_{\\mathrm{ss}}$, note that steady state satisfies $0 = -k_{d} D_{\\mathrm{ss}} + u_{\\mathrm{ss}}$ and $0 = -k_{r} R_{\\mathrm{ss}} + g D_{\\mathrm{ss}}$. Thus $D_{\\mathrm{ss}} = u_{\\mathrm{ss}}/k_{d}$ and $R_{\\mathrm{ss}} = (g/k_{r}) D_{\\mathrm{ss}}$. For $R_{\\mathrm{ss}} = D_{\\mathrm{ss}}$, we require $g = k_{r}$.\n\nGiven chronic overuse prior to $t=0$, we have $D(0^{-}) = 1$, $R(0^{-}) = 1$, and $u_{\\mathrm{ss}} = k_{d}$ from $D_{\\mathrm{ss}} = 1$.\n\nDefine $T = 72$. The congestion relative to baseline is $C(t) = R(t) - D(t)$ with $a = b = 1$. The AUEC is $Q = \\int_{0}^{T} C(t)\\, dt$.\n\nAbrupt cessation case:\n\n- Input: $u(t) = 0$ for $t \\in [0, T]$.\n- Drug effect: $ \\frac{dD}{dt} = -k_{d} D $ with $D(0) = 1$, hence $D_{\\mathrm{abrupt}}(t) = \\exp(-k_{d} t)$.\n- Receptor desensitization: $ \\frac{dR}{dt} = -k_{r} R + k_{r} D_{\\mathrm{abrupt}}(t)$ with $R(0) = 1$.\n\nSolve the linear nonhomogeneous equation by variation of parameters (convolution form). The solution is\n$$\nR_{\\mathrm{abrupt}}(t) = \\exp(-k_{r} t) R(0) + k_{r} \\int_{0}^{t} \\exp\\!\\big(-k_{r} (t-s)\\big) D_{\\mathrm{abrupt}}(s)\\, ds.\n$$\nWith $R(0) = 1$ and $D_{\\mathrm{abrupt}}(s) = \\exp(-k_{d} s)$, compute the integral:\n$$\n\\int_{0}^{t} \\exp\\!\\big(-k_{r} (t-s)\\big) \\exp(-k_{d} s)\\, ds\n= \\exp(-k_{r} t) \\int_{0}^{t} \\exp\\!\\big((k_{r}-k_{d}) s\\big)\\, ds\n= \\exp(-k_{r} t) \\frac{\\exp\\!\\big((k_{r}-k_{d}) t\\big) - 1}{k_{r} - k_{d}}.\n$$\nThus\n$$\nR_{\\mathrm{abrupt}}(t) = \\exp(-k_{r} t) + k_{r} \\exp(-k_{r} t) \\frac{\\exp\\!\\big((k_{r}-k_{d}) t\\big) - 1}{k_{r} - k_{d}}\n= \\exp(-k_{r} t) \\left[ 1 + \\frac{k_{r}}{k_{r} - k_{d}} \\left( \\exp\\!\\big((k_{r}-k_{d}) t\\big) - 1 \\right) \\right].\n$$\nIt is convenient to rewrite this as a sum of exponentials:\n$$\nR_{\\mathrm{abrupt}}(t) = - \\frac{k_{d}}{k_{r} - k_{d}} \\exp(-k_{r} t) + \\frac{k_{r}}{k_{r} - k_{d}} \\exp(-k_{d} t).\n$$\nTherefore,\n$$\nC_{\\mathrm{abrupt}}(t) = R_{\\mathrm{abrupt}}(t) - D_{\\mathrm{abrupt}}(t)\n= - \\frac{k_{d}}{k_{r} - k_{d}} \\exp(-k_{r} t) + \\frac{k_{r}}{k_{r} - k_{d}} \\exp(-k_{d} t) - \\exp(-k_{d} t).\n$$\nCombine the $\\exp(-k_{d} t)$ terms:\n$$\n\\frac{k_{r}}{k_{r} - k_{d}} \\exp(-k_{d} t) - \\exp(-k_{d} t) = \\left( \\frac{k_{r}}{k_{r} - k_{d}} - 1 \\right) \\exp(-k_{d} t) = \\frac{k_{d}}{k_{r} - k_{d}} \\exp(-k_{d} t).\n$$\nThus\n$$\nC_{\\mathrm{abrupt}}(t) = \\frac{k_{d}}{k_{r} - k_{d}} \\left[ \\exp(-k_{d} t) - \\exp(-k_{r} t) \\right].\n$$\nThe AUEC for abrupt cessation over $[0, T]$ is\n$$\nQ_{\\mathrm{abrupt}} = \\int_{0}^{T} C_{\\mathrm{abrupt}}(t)\\, dt\n= \\frac{k_{d}}{k_{r} - k_{d}} \\left[ \\int_{0}^{T} \\exp(-k_{d} t)\\, dt - \\int_{0}^{T} \\exp(-k_{r} t)\\, dt \\right].\n$$\nUsing $ \\int_{0}^{T} \\exp(-\\alpha t)\\, dt = \\frac{1 - \\exp(-\\alpha T)}{\\alpha} $, we obtain\n$$\nQ_{\\mathrm{abrupt}} = \\frac{k_{d}}{k_{r} - k_{d}} \\left[ \\frac{1 - \\exp(-k_{d} T)}{k_{d}} - \\frac{1 - \\exp(-k_{r} T)}{k_{r}} \\right].\n$$\n\nGradual dose spacing case:\n\n- Input is approximated as $u(t) = u_{\\mathrm{ss}}/3 = k_{d}/3$ for $t \\in [0, T]$.\n- Drug effect satisfies $ \\frac{dD}{dt} = -k_{d} D + k_{d}/3 $ with $D(0) = 1$. The steady-state level for this input is $D_{\\infty} = (k_{d}/3)/k_{d} = 1/3$. Hence\n$$\nD_{\\mathrm{grad}}(t) = D_{\\infty} + \\left( D(0) - D_{\\infty} \\right) \\exp(-k_{d} t) = \\frac{1}{3} + \\frac{2}{3} \\exp(-k_{d} t).\n$$\n- Receptor desensitization satisfies $ \\frac{dR}{dt} = -k_{r} R + k_{r} D_{\\mathrm{grad}}(t) $ with $R(0) = 1$. The solution is\n$$\nR_{\\mathrm{grad}}(t) = \\exp(-k_{r} t) R(0) + k_{r} \\int_{0}^{t} \\exp\\!\\big(-k_{r} (t-s)\\big) D_{\\mathrm{grad}}(s)\\, ds.\n$$\nCompute the integral by splitting $D_{\\mathrm{grad}}(s) = \\frac{1}{3} + \\frac{2}{3} \\exp(-k_{d} s)$:\n$$\nk_{r} \\int_{0}^{t} \\exp\\!\\big(-k_{r} (t-s)\\big) \\left( \\frac{1}{3} \\right) ds = \\frac{1}{3} \\left( 1 - \\exp(-k_{r} t) \\right),\n$$\n$$\nk_{r} \\int_{0}^{t} \\exp\\!\\big(-k_{r} (t-s)\\big) \\left( \\frac{2}{3} \\exp(-k_{d} s) \\right) ds\n= \\frac{2}{3} k_{r} \\exp(-k_{r} t) \\frac{\\exp\\!\\big((k_{r} - k_{d}) t\\big) - 1}{k_{r} - k_{d}}.\n$$\nTherefore\n$$\nR_{\\mathrm{grad}}(t) = \\exp(-k_{r} t) + \\frac{1}{3} \\left( 1 - \\exp(-k_{r} t) \\right) + \\frac{2}{3} k_{r} \\exp(-k_{r} t) \\frac{\\exp\\!\\big((k_{r} - k_{d}) t\\big) - 1}{k_{r} - k_{d}}.\n$$\nNow compute congestion:\n$$\nC_{\\mathrm{grad}}(t) = R_{\\mathrm{grad}}(t) - D_{\\mathrm{grad}}(t).\n$$\nSubstitute $R_{\\mathrm{grad}}(t)$ and $D_{\\mathrm{grad}}(t) = \\frac{1}{3} + \\frac{2}{3} \\exp(-k_{d} t)$ and simplify. First note that $\\frac{1}{3}$ cancels between $R_{\\mathrm{grad}}(t)$ and $D_{\\mathrm{grad}}(t)$, leaving\n$$\nC_{\\mathrm{grad}}(t) = \\frac{2}{3} \\exp(-k_{r} t) + \\frac{2}{3} k_{r} \\exp(-k_{r} t) \\frac{\\exp\\!\\big((k_{r} - k_{d}) t\\big) - 1}{k_{r} - k_{d}} - \\frac{2}{3} \\exp(-k_{d} t).\n$$\nFactor $\\frac{2}{3}$ and group terms:\n$$\nC_{\\mathrm{grad}}(t) = \\frac{2}{3} \\left[ \\exp(-k_{r} t) - \\exp(-k_{d} t) + \\frac{k_{r}}{k_{r} - k_{d}} \\left( \\exp(-k_{d} t) - \\exp(-k_{r} t) \\right) \\right].\n$$\nThe coefficients combine to yield\n$$\nC_{\\mathrm{grad}}(t) = \\frac{2}{3} \\cdot \\frac{k_{d}}{k_{r} - k_{d}} \\left[ \\exp(-k_{d} t) - \\exp(-k_{r} t) \\right].\n$$\nComparing with $C_{\\mathrm{abrupt}}(t)$, we find\n$$\nC_{\\mathrm{grad}}(t) = \\frac{2}{3} \\, C_{\\mathrm{abrupt}}(t) \\quad \\text{for all } t \\in [0, T].\n$$\nTherefore, the areas under the effect curves over any horizon $[0, T]$ satisfy\n$$\nQ_{\\mathrm{gradual}} = \\int_{0}^{T} C_{\\mathrm{grad}}(t)\\, dt = \\frac{2}{3} \\int_{0}^{T} C_{\\mathrm{abrupt}}(t)\\, dt = \\frac{2}{3} \\, Q_{\\mathrm{abrupt}}.\n$$\nHence the requested ratio is\n$$\n\\frac{Q_{\\mathrm{abrupt}}}{Q_{\\mathrm{gradual}}} = \\frac{Q_{\\mathrm{abrupt}}}{(2/3) Q_{\\mathrm{abrupt}}} = \\frac{3}{2}.\n$$\nThis result is independent of the specific values of $k_{d}$, $k_{r}$, and $T$ under the stated linear PK/PD structure and the choice $g = k_{r}$ ensuring $R_{\\mathrm{ss}} = D_{\\mathrm{ss}}$.", "answer": "$$\\boxed{\\frac{3}{2}}$$", "id": "5053084"}]}